EC Number   |
Application |
Reference |
|---|
    1.17.4.1 | drug development |
class Ib NrdF requires manganese under conditions in which the organism is pathogenic. Considering that streptococci and other pathogens, including enterococci, staphylococci, and Bacillus sp., contain class Ib ribonucleotide reductase as their only aerobic RNR, prevention of dimanganese-tyrosyl radical (Mn(III)2-Y(*)) cofactor formation in the class Ib ribonucleotide reductase may be an attractive target for new antimicrobials |
-, 745317 |
| 1.17.4.1 | drug development |
ribonucleotide reductase is a key enzyme in DNA synthesis and cell growth control and represents an excellent target for anticancer therapy. 5'-O-valproyl-3'-C-methyladenosine inhibits ribonucleotide reductase activity by competing with ATP as an allosteric effector and concomitantly reduces the intracellular deoxyribonucleoside triphosphate pools. In contrast to previously used ribonucleotide reductase nucleoside analogs does not require intracellular kinases for its activity and therefore holds promise against drug resistant tumors with downregulated nucleoside kinases |
744504 |
| 1.17.4.1 | drug development |
the enzyme is an important therapeutic target for anticancer drugs |
702551 |
| 1.17.4.1 | drug development |
the thiazolyl hydrazones VG12, VG19, and VG22 plus arabinofuranosylcytosine might be able to improve conventional chemotherapeutic regimens for the treatment of human malignancies such as acute promyelocytic or chronic myelogenous leukemia |
744958 |
| 1.17.4.1 | medicine |
combination of (2E)-2-(anthracen-9-ylmethylidene)-N-hydroxyhydrazinecarboximidamide with the first-line antileukemic agent arabinofuranosylcytosine, Ara-C, synergistically potentiates the antineoplastic effects of Ara-C |
726918 |
| 1.17.4.1 | medicine |
high expression of ribonucleotide reductase subunit M2 (RRM2) correlates with poor prognosis of hepatocellular carcinoma. High RRM2 protein expression might be a useful marker for predicting early recurrence and may be a marker for poor prognosis of hepatocellular carcinoma after curative hepatectomy |
745050 |
| 1.17.4.1 | medicine |
in transgenic human lung and colon cancer lines expressing xanthine oxidase regulatory subunit RRM1, G2 cell cycle arrest, apoptosis, and efficient DNA damage repair are induced |
672909 |
| 1.17.4.1 | medicine |
in transgenic mice expressing xanthine oxidase regulatory subunit RRM1, carcinogen-induced lung tumor formation is significantly suppressed. RRM1 transgenic animals repair chemically induced DNA damage with greater efficiency than control animals |
672909 |
| 1.17.4.1 | medicine |
ribonucleotide reductase is a therapeutic target for DNA replication-dependent diseases such as cancer in humans |
686137 |
| 1.17.4.1 | medicine |
skin fibroblasts isolated from a patient with a lethal homozygous missense mutation of ioform p53R2 grow normally in culture with an unchanged complement of mtDNA. During active growth, the four dNTP pools do not differ in size from normal controls, whereas during quiescence, the dCTP and dGTP pools decrease to 50% of the control. On withdrawal of ethidium bromide depleting cell of mitochondrial DNA, mitochondrial DNA recovers equally well in cycling mutant and control cells, whereas during quiescence, the mutant fibroblasts remain deficient. Addition of deoxynucleosides to the medium increases intracellular dNTP pools and normalizes mtDNA synthesis. Quiescent mutant fibroblasts are also deficient in the repair of UV-induced DNA damage |
728677 |
